search
Back to results

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine (QoL)

Primary Purpose

Diabetes Type 2

Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
Insulin Glargine
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

lists of inclusion and exclusion criteria:

Inclusion Criteria:

  • Patients with type 2diabetes inadequately controlled on a combination of OAD + NPH insulin for more than three months
  • Stable OAD therapy for at least three months, according to the following specified daily dose: glibenclamide> 3, 5 mg, glipizid >5 mg, glimeperid >2mg, metformin>1000 mg, acarbose >150 mg
  • HbA1c > 7,0%
  • Ability to perform QoL assessment
  • Body Mass Indes: women <30 and men <32

Exlusion criteria:

  • Autoimmune diabetes, as defined by WHO
  • Ongoing treatment with tiasolidindion drug
  • Retinopathy with surgical treatment during preceding three months of study entry or requiring treatment within three months after study entry
  • Drug abuse
  • Hypersensitivity to insulin glagine excipients

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Sanofi-Aventis Administrative Office

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

insulin glargine

Outcomes

Primary Outcome Measures

The fear of hypoglycaemia scale (HFS)
12 - Item Well-Being Questionnaaire (WBQ12)
Glycaemic controll will be asessed by HbA1c values

Secondary Outcome Measures

Incidence of symptomatic hypoglycemia and severe hypoglycemia

Full Information

First Posted
August 17, 2007
Last Updated
December 4, 2009
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00518427
Brief Title
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
Acronym
QoL
Official Title
A Multicenter Clinical Trial to Evaluate Quality of Life in Patients With Type 2 Diabetes Before and After Changing Therapy to a Combination of Insulin Glargine and Oral Antidiabetic Drugs in a Real Life Situation
Study Type
Interventional

2. Study Status

Record Verification Date
December 2009
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
March 2008 (Actual)
Study Completion Date
March 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Sanofi

4. Oversight

5. Study Description

Brief Summary
Primary objective: To assess quality of Life (QoL) changes and treatment satisfaction in a real life situation in patients with Type 2 diabetes inadequately controlled on a combination of oral antidiabetic drugs (OAD) plus Neutral Protamine Hagedrone (NHP) insulin treatment that are switched to insulin glargine. Secondary objective: To determine: change in HbA1c, comparision of the incidence of symptomatic hypoglycemia and severe hypoglycemia before and after introduction of insulin glargine, change in weight, change in insulin dose.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
insulin glargine
Intervention Type
Drug
Intervention Name(s)
Insulin Glargine
Intervention Description
Lantus (insulin glargine [rDNA origin] injection), individual dosing , subcutaneous injection, 100 IU/ml. Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment.
Primary Outcome Measure Information:
Title
The fear of hypoglycaemia scale (HFS)
Time Frame
before the switch to insulin glargine and at 3 and 9 months of follow up.
Title
12 - Item Well-Being Questionnaaire (WBQ12)
Time Frame
before the switch to insulin glargine and at 3 and 9 months of follow up.
Title
Glycaemic controll will be asessed by HbA1c values
Time Frame
week 12 and week 40
Secondary Outcome Measure Information:
Title
Incidence of symptomatic hypoglycemia and severe hypoglycemia
Time Frame
sreening to follow-up phases

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
lists of inclusion and exclusion criteria: Inclusion Criteria: Patients with type 2diabetes inadequately controlled on a combination of OAD + NPH insulin for more than three months Stable OAD therapy for at least three months, according to the following specified daily dose: glibenclamide> 3, 5 mg, glipizid >5 mg, glimeperid >2mg, metformin>1000 mg, acarbose >150 mg HbA1c > 7,0% Ability to perform QoL assessment Body Mass Indes: women <30 and men <32 Exlusion criteria: Autoimmune diabetes, as defined by WHO Ongoing treatment with tiasolidindion drug Retinopathy with surgical treatment during preceding three months of study entry or requiring treatment within three months after study entry Drug abuse Hypersensitivity to insulin glagine excipients The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Margareta Olsson-Birgersson
Organizational Affiliation
sanofi-aventis, Sweden
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-Aventis Administrative Office
City
Bromma
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine

We'll reach out to this number within 24 hrs